H.C. Wainwright analyst Pat Trucchio adjusted the price target for Cybin Inc. (NYSE:CYBN) stock, lowering it to $150.00 from the previous $190.00 while maintaining a Buy rating on the company.

Mental health professionals reveal the hidden signs of anxiety disorders affecting millions of Americans, from mysterious ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Lexapro is an antidepressant medication commonly prescribed for anxiety. Here's how to know the best time of day to take it.

One of the most effective methods is therapy, particularly cognitive-behavioral therapy (CBT). CBT helps individuals identify and change negative thought patterns that contribute to anxiety.

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Cybin (CYBN) to $73 from $86 and keeps a Buy rating on the shares. The ...

Political anxiety has become a dominant theme in our culture. We present some of the prominent features and suggestions about ...

Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing ...

You're probably familiar with the symptoms of anxiety: feeling worried, racing thoughts, and being irritable. But while being ...

The business offers therapy services for individuals with various experiences including anxiety, OCD and depression.

A new Cochrane review showed SSRIs and SNRIs outperform placebo for GAD with similar dropout rates, but questions remain ...